<DOC>
	<DOCNO>NCT02409563</DOCNO>
	<brief_summary>In clinical trial treatment allergic rhinitis significant reduction total symptom score compare baseline demonstrate use nasal budesonide.Previous result adult show assessment monitoring del nasal fractional exhale nitric oxide ( nFeNO ) useful control inflammation nasal allergic rhinitis . Primary objective study evaluate efficacy nasal budesonide ( aqueous solution ) nasal inflammation marker ( nFeNO ) . Secondary outcome evaluation : change total nasal symptom score ( Total Symptom Score , T5SS ) , change cell count nasal lavage ( LN ) change report sleep quality ( Pittsburgh Sleep Quality Index , PSQI ) .</brief_summary>
	<brief_title>Nasal Budesonide Efficacy Nasal FeNO Children With Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>history allergic rhinitis least 1 year child age 6 14 year Total Symptom Score ( T5SS ) 6 last 4 day screen visit sign acute respiratory infection systemic immunological metabolic disease major malformation upper airways topical systemic therapy antibiotic , antihistamine corticosteroid 30 day prior study patient active smoker</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>